Contributions
Abstract: PB1754
Type: Publication Only
Session title: Quality of life, palliative care, ethics and health economics
Background
Significant attention has been placed on recognizing impact of symptom burden and treatment-related toxicities on patients’ health-related quality of life (HRQoL) since these would have an effect on treatment tolerability and adherence. In the Philippines, the only locally available TKIs are Imatinib and Nilotinib. Access and sustainability for the newer TKIs such as Dasatinib, Ponatinib and Bosutinib as second- or third-line agents is made possible with the help of The Max Foundation via their Max Access Solutions (MAS). There is paucity of published local data on HRQoL outcomes on Filipino CML patients treated with newer-generation tyrosine kinase inhibitors (TKIs).
Aims
This study determined the HRQoL of Chronic Myeloid Leukemia (CML) patients on newer-generation TKIs using the Filipino-version of the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire©.
Methods
A single-center, cross-sectional study included CML patients, aged 19, with stable comorbidities, taking newer-generation-TKIs as second-or-third line treatment (Dasatinib, Ponatinib and Bosutinib) for 3 months. HRQoL was assessed using the Filipino-version of the FACT-Leu© questionnaire. Descriptive statistics was used to summarize patients’ demographic and clinical characteristics. Independent sample T-test and one-way analysis of variance was used to test significant difference between groups. STATA 13.1 was used for data analysis.
Results
All 33 patients were in chronic-phase. Newer-generation TKIs used were: Dasatinib (54.55%), Bosutinib (30.30%) and Ponatinib (15.15%). Mean scores: Trial Outcomes Index (106.15 + 12.27), FACT-G score (94.79 + 10.74) and FACT-Leu score (151.58 + 17.25) showed good HRQoL. There was no significant difference between HRQOL with sex, marital status, educational attainment, employment, adverse drug event with concomitant dose adjustment and newer-generation TKI used (p-value 0.786, 0.764, 0.764, 0.944, 0.864, 0.554); and insufficient evidence to conclude a correlation between overall FACT-Leu score to age, CML and treatment duration (p-value 0.7389, 0.4738, 0.6984).
Conclusion
HRQoL evaluation is a vital part of disease management. This study demonstrated that Filipino CML patients using newer-generation TKIs as second or third-line therapy showed good HRQoL regardless of age, sex, marital status, educational attainment, employment, CML duration, treatment duration, presence or absence of adverse drug event with concomitant dose adjustment and newer-generation TKI used.
Keyword(s): Chronic myeloid leukemia, Quality of life, Tyrosine kinase inhibitor
Abstract: PB1754
Type: Publication Only
Session title: Quality of life, palliative care, ethics and health economics
Background
Significant attention has been placed on recognizing impact of symptom burden and treatment-related toxicities on patients’ health-related quality of life (HRQoL) since these would have an effect on treatment tolerability and adherence. In the Philippines, the only locally available TKIs are Imatinib and Nilotinib. Access and sustainability for the newer TKIs such as Dasatinib, Ponatinib and Bosutinib as second- or third-line agents is made possible with the help of The Max Foundation via their Max Access Solutions (MAS). There is paucity of published local data on HRQoL outcomes on Filipino CML patients treated with newer-generation tyrosine kinase inhibitors (TKIs).
Aims
This study determined the HRQoL of Chronic Myeloid Leukemia (CML) patients on newer-generation TKIs using the Filipino-version of the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire©.
Methods
A single-center, cross-sectional study included CML patients, aged 19, with stable comorbidities, taking newer-generation-TKIs as second-or-third line treatment (Dasatinib, Ponatinib and Bosutinib) for 3 months. HRQoL was assessed using the Filipino-version of the FACT-Leu© questionnaire. Descriptive statistics was used to summarize patients’ demographic and clinical characteristics. Independent sample T-test and one-way analysis of variance was used to test significant difference between groups. STATA 13.1 was used for data analysis.
Results
All 33 patients were in chronic-phase. Newer-generation TKIs used were: Dasatinib (54.55%), Bosutinib (30.30%) and Ponatinib (15.15%). Mean scores: Trial Outcomes Index (106.15 + 12.27), FACT-G score (94.79 + 10.74) and FACT-Leu score (151.58 + 17.25) showed good HRQoL. There was no significant difference between HRQOL with sex, marital status, educational attainment, employment, adverse drug event with concomitant dose adjustment and newer-generation TKI used (p-value 0.786, 0.764, 0.764, 0.944, 0.864, 0.554); and insufficient evidence to conclude a correlation between overall FACT-Leu score to age, CML and treatment duration (p-value 0.7389, 0.4738, 0.6984).
Conclusion
HRQoL evaluation is a vital part of disease management. This study demonstrated that Filipino CML patients using newer-generation TKIs as second or third-line therapy showed good HRQoL regardless of age, sex, marital status, educational attainment, employment, CML duration, treatment duration, presence or absence of adverse drug event with concomitant dose adjustment and newer-generation TKI used.
Keyword(s): Chronic myeloid leukemia, Quality of life, Tyrosine kinase inhibitor